Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 20

Results For "investigation"

621 News Found

GE HealthCare launches game-changing StarGuide GX for precision nuclear medicine
Digitisation | December 01, 2025

GE HealthCare launches game-changing StarGuide GX for precision nuclear medicine

StarGuide GX delivers ultra-high sensitivity and high-resolution imaging, enabling fast, confident diagnostics


Akums Drugs appoints Yuvraj Datta as President – Operational Strategy & Excellence
People | November 28, 2025

Akums Drugs appoints Yuvraj Datta as President – Operational Strategy & Excellence

Most recently, Yuvraj was the Director of Operations, Business Development & Process Excellence at Zeon Lifesciences Ltd


Bayer’s experimental stroke drug could reshape secondary stroke prevention
Clinical Trials | November 24, 2025

Bayer’s experimental stroke drug could reshape secondary stroke prevention

Millions of stroke survivors across the world may soon have a new defense


Merck’s two-drug HIV regimen hits phase 3 success
Clinical Trials | November 21, 2025

Merck’s two-drug HIV regimen hits phase 3 success

The study successfully met its primary endpoint, demonstrating similar rates of viral suppression for DOR/ISL compared to Biktarvy at 48 weeks


Roche’s Giredestrant sets new benchmark in early breast cancer treatment
Clinical Trials | November 19, 2025

Roche’s Giredestrant sets new benchmark in early breast cancer treatment

The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in invasive disease-free survival


Merck to acquire Cidara Therapeutics for $9.2 billion
Biotech | November 15, 2025

Merck to acquire Cidara Therapeutics for $9.2 billion

Diversifying its portfolio to include late-phase antiviral agent


Daiichi Sankyo launches first-in-human trial of innovative cancer therapy
Clinical Trials | November 14, 2025

Daiichi Sankyo launches first-in-human trial of innovative cancer therapy

The trial will evaluate safety endpoints including dose-limiting toxicities and adverse events


UK MHRA finds gut microbiome research unreliable across labs
R&D | November 14, 2025

UK MHRA finds gut microbiome research unreliable across labs

False positive rates?ranged from 0% to 41%, meaning some labs incorrectly identified bacteria that weren’t present in the sample


Philogen updates on Fibromun clinical study developments
Clinical Trials | November 13, 2025

Philogen updates on Fibromun clinical study developments

FIBROSARC did not meet its primary PFS endpoint in the final analysi